期刊文献+

硝苯地平联合卡托普利治疗原发性高血压临床分析 被引量:26

硝苯地平联合卡托普利治疗原发性高血压临床分析
下载PDF
导出
摘要 目的探讨硝苯地平联合卡托普利治疗原发性高血压临床疗效分析。方法回顾分析116例原发性高血压患者临床资料,随机分为观察组和对照组各58例,停用其他降压药两周以上,均调节降压饮食,合理化运动。对照组给予卡托普利口服治疗,观察组在对照组的基础上给予口服硝苯地平缓释片治疗,8周后进行疗效评价。结果观察组显效率51.7%,有效率37.9%,总有效率89.7%;对照组显效率31%,有效率39.7%,总有效率70.7%,观察组的显效率和总有效率均明显高于对照组,两者比较差异有统计学意义(P<0.05)。治疗后治疗组收缩压和舒张压较对照组治疗后降低,两者比较差异有统计学意义(P<0.05)。结论硝苯地平联合卡托普利治疗原发性高血压作用更强,效果更好,值得临床进一步推广应用。 Objective To investigate the nifedipine combined with captopril in the treatment of primary hypertension clinical analysis. Methods The samples were retrospectively analyzed in 116 patients with primary hypertension patient clinical material, were randomly divided into the observation group and the control group with 58 cases in each group, no other antthypertensive drugs for more than two weeks, both buck diet, reasonable exercise. The control group was given captopril oral treatment, the observation group in the control group was given based on oral nifedipine sustained release tablets in the treatment, 8 weeks after curative effect evaluation. In the observation group, the markedly effective rate was 51.7%, with an efficiency of 37.9%, the total effective rate was 89.7%; the control group markedly effective rate was 31%, with an efficiency of 39.7%, the total efficiency of 70.7%, the observation group the significant effective rate and total effective rate were significantly higher than those in the control group, both had a significant difference (P〈0.05). After the treatment of systolic and diastolic blood pressure in treatment group than in the control group decreased after treatment, both had a significant difference (P〈0.05). Conclusion nifedipine combined with captopril in the treatment of primary hypertension effect stronger, better effect, worthy of further clinical application.
作者 廖承广
出处 《当代医学》 2012年第7期57-58,共2页 Contemporary Medicine
关键词 卡托普利 硝苯地平 原发性高血压 Captopril Nifedipine In essential hypertension
  • 相关文献

参考文献8

二级参考文献30

  • 1陶萍.硝苯地平控释片的制剂特点[J].中华心血管病杂志,1994,22(5):326-327. 被引量:20
  • 2柯元南.高血压的联合治疗[J].中国医师进修杂志(内科版),2006,29(1):3-6. 被引量:19
  • 3麻连荣.老年人抗高血压药物的选择应用[J].中国医药导报,2007,4(08Z):168-168. 被引量:3
  • 4Hingorani AD.Endothelial nitric oxide synthase polymorphisms and hypertension[J].Curr Hypertens Rep,2003 Feb,5(1):19.
  • 5Ying Wei-Zhong,Xia H,et al.Nitric oxide synthase(NOS2)mutation in Dahl/Rapp Rats decreases enzyme stability[J].Circ Res,2001,89:317-322.
  • 6Loscalzo J.Salt-sensitive hypertension and inducible nitric oxide synthase.Form-function dichotomy of a coding region mutation,mutatis mutandir[J].Circ Res,2001,89:292-294.
  • 7Iwai N,Inagami T,Kinoshita M.Molecular genetics of the SA gene[J].Clin Exp Pharmacol Physiol,1994 Nov,21(11):913.
  • 8Nabika T.Genetic analysis of responsible genes for essential hypertension.Rinsho Byori,1997 Feb,45(2):107-111.
  • 9Rao MS.Pathogenesis and consequences of essential hypertension[J].J Indian Med Assoc,2003 Apr,101(4):251.
  • 10Fisher ND,Hurwitz S,Jeunemaitre X,et al.Familial aggregation of low-renin hypertension[J].Hypertension,2002 Apr,39(4):914-918.

共引文献2972

同被引文献123

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部